Establishing an immune correlate of protection for Nipah virus in nonhuman primates
Victor H. Leyva-Grado, Dominique Promeneur, Krystle N. Agans, Glorie G. Lazaro, Viktoriya Borisevich, Daniel J. Deer, Amara Luckay, Michael Egan, Antony S. Dimitrov, B. Small, Christopher C. Broder, Robert W. Cross, Svetlana Hamm, Thomas W. Geisbert
Abstract
The limited but recurrent outbreaks of the zoonotic Nipah virus (NiV) infection in humans, its high fatality rate, and the potential virus transmission from human to human make NiV a concerning threat with pandemic potential. There are no licensed vaccines to prevent infection and disease. A recombinant Hendra virus soluble G glycoprotein vaccine (HeV-sG-V) candidate was recently tested in a Phase I clinical trial. Because NiV outbreaks are sporadic, and with a few cases, licensing will likely require an alternate regulatory licensing pathway. Therefore, determining a reliable vaccine correlate of protection (CoP) will be critical. We assessed the immune responses elicited by HeV-sG-V in African Green monkeys and its relationship with protection from a NiV challenge. Data revealed values of specific binding and neutralizing antibody titers that predicted survival and allowed us to establish a mechanistic CoP for NiV Bangladesh and Malaysia strains.